Overview

Vasoactive Drugs in Intensive Care Unit

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:
0

Participant gender:
All

Summary

The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Chicago

Treatments:

Arginine Vasopressin
Epinephrine
Epinephryl borate
Norepinephrine
Oxymetazoline
Phenylephrine
Racepinephrine
Synephrine
Vasoconstrictor Agents
Vasopressins

Criteria

Inclusion Criteria:

1. Age greater than or equal to 18 years old

2. Requirement for vasoactive drugs via a central venous catheter for the treatment of
shock. Shock will be defined as mean arterial pressure less than 70 mmHg or systolic
blood pressure less than 100 mmHg despite administration of at least 1000 mL of
crystalloid or 500 mL of colloid, unless there is an elevation in the central venous
pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg
coupled with signs of tissue hypoperfusion (e.g. altered mental state, mottled skin,
urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2
mmol per liter).

Exclusion Criteria:

1. Cardiopulmonary arrest

2. Pregnancy

3. Severe right heart failure